Literature DB >> 16274024

Successful treatment of electrical storm with oral quinidine in Brugada syndrome.

Katia Bettiol1, Lorella Gianfranchi, Salvatore Scarfò, Federico Pacchioni, Mario Pedaci, Paolo Alboni.   

Abstract

A patient implanted with a cardioverter-defibrillator for symptomatic Brugada syndrome was referred to our hospital 17 months later because of recurrent shocks due to ventricular fibrillation (VF). Isoprenaline was intravenously infused and prevented VF episodes, but VF recurred after every attempt of drug discontinuation. A total of 34 shocks were recorded over 25 days. Subsequently, we treated the patient with oral quinidine and the drug suppressed the electrical storm and prevented VF episodes during a follow-up period of 3 years. This case report, together with few others reported in the literature, suggests a role of oral quinidine in the treatment of electrical storm in Brugada syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274024

Source DB:  PubMed          Journal:  Ital Heart J        ISSN: 1129-471X


  4 in total

1.  Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally.

Authors:  J K Jongman; N Jepkes-Bruin; A R Ramdat Misier; W P Beukema; P P H M Delnoy; H Oude Lutttikhuis; J H E Dambrink; J C A Hoorntje; A Elvan
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

Review 2.  Pharmacological Therapy in Brugada Syndrome.

Authors:  Oholi Tovia Brodie; Yoav Michowitz; Bernard Belhassen
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

Review 3.  Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review.

Authors:  Anuj Rastogi; Dylan Viani-Walsh; Shareef Akbari; Nicholas Gall; Fiona Gaughran; John Lally
Journal:  Gen Hosp Psychiatry       Date:  2020-10-06       Impact factor: 3.238

4.  Successful treatment of cardiac electrical storm in dilated cardiomyopathy using esmolol: A case report.

Authors:  L I Li; Yuan-Li Zhou; Xue-Jing Zhang; Hua-Ting Wang
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.